Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEQUEL: EEG study of Elayta in mild to moderate Alzheimer's disease
NCT04735536Phase 2Completed
- Sponsor
- Cognition Therapeutics, Inc.
- Start
- Jul 2020
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pirfenidone in Alzheimer's disease (AD), sponsored by Cognition Therapeutics, Inc.. Started Jul 2020; status: completed.
02
Drugs
pirfenidone
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04735536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04735536.